Volume | 23,137 |
|
|||||
News | - | ||||||
Day High | 0.4598 | Low High |
|||||
Day Low | 0.4301 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Virios Therapeutics Inc | VIRI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.4378 | 0.4301 | 0.4598 | 0.4252 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
139 | 23,137 | $ 0.4426671 | $ 10,242 | - | 0.279 - 2.42 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:50:30 | 24 | $ 0.4358 | USD |
Virios Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.86M | 19.26M | - | 0 | -5.3M | -0.28 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Virios Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VIRI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.44 | 0.4747 | 0.401 | 0.4308165 | 93,958 | -0.0044 | -1.00% |
1 Month | 0.49 | 0.58 | 0.401 | 0.4941712 | 204,990 | -0.0544 | -11.10% |
3 Months | 0.4241 | 0.6288 | 0.279 | 0.4326544 | 313,178 | 0.0115 | 2.71% |
6 Months | 0.5558 | 1.04 | 0.279 | 0.5948803 | 396,883 | -0.1202 | -21.63% |
1 Year | 1.20 | 2.42 | 0.279 | 1.02 | 980,461 | -0.7644 | -63.70% |
3 Years | 5.61 | 9.1109 | 0.218951 | 1.09 | 495,324 | -5.17 | -92.24% |
5 Years | 13.76 | 14.39 | 0.218951 | 1.57 | 475,165 | -13.32 | -96.83% |
Virios Therapeutics Description
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia. |